Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Astellas Pharma China, Inc.
Shenyang, Liaoning, Chinaastellas.com ↗
- Ownership
- Private
- Employees
- ~17000
- Development stage
- Other
01
Overview
Astellas Pharma (including the China operation) is a major multinational pharmaceutical company with approved products and late-stage assets across oncology, immunology, nephrology, and other areas. Top marketed drugs include enzalutamide (Xtandi), peficitinib, and recent advances in monoclonal antibodies and antibody-drug conjugates for cancers, with some programs in Phase 3 or recently approved in the US, Japan, and China[1][6].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugate
- Industry
- Pharma
02
Partnerships
Beyond the preview
Go deeper on Astellas Pharma China, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astellas Pharma China, Inc..